Tokyo, Japan (PRWEB) December 03, 2012
Japan Bioinformatics, today announced results of a study on the impact three popular mapping tools have on the results of SNP discovery experiments and the analysis of sequence data.
Mutation discovery, especially discovery of single nucleotide polymorphisms (SNPs) is an extremely popular analysis of sequence data in many types of research, including cancer. The data from Next Generation Sequencing (NGS) devices provides a very cost-effective and convenient source of information. Additionally, the proliferation of NGS-focused data analysis tools makes this type of research easily accessible to individual researchers.
Japan Bioinformatics recently published a study, which utilizes Simbiot®, a cloud-based next generation sequencing data analysis tool, to explore the impact three popular mapping tools have on the results of SNP discovery experiments.
Bowtie, Bowtie2 and BWA mapping tools were tested using data from a human cancer panel, a human exome and Caenhorhabditis elegans whole genome. In all three cases, the results were consistent:
Bowtie detected the smallest number of SNPs and almost no insertions or deletions (INDELs)
- Bowtie2 and BWA were able to detect a similar number of mutations
- There were significant discrepancies between the SNPs detected using Bowtie2 and those detected using BWA
- The results of INDEL analysis in the human exome data set show that 67% of the filtered, high quality INDELs were common between mutations detected using Bowtie2 and those detected using BWA genome aligners.
For the complete results of the analysis, download the white paper,
About Japan Bioinformatics
Page: 1 2 Related biology technology :1
Copyright©2012 Vocus, Inc.
All rights reserved
. Sosei Group Corporation QVA149 Phase III Study Meets Primary Endpoint in Reducing Exacerbations in COPD Patients and Filings in EU and Japan by End of Year2
. First Baby With Artificial Heart in Japan3
. Snoasis Medical Initiates Distribution in Japan Through Hausten Healthcare4
. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology5
. Immunomic Therapeutics Receives IND Authorization for Phase I Study of JRC-LAMP-Vax Vaccine to Treat Japanese Red Cedar (Sugi) Allergy6
. Regulus Receives Allowance from Japan and U.S. Patent Offices for HCV Intellectual Property, Expanding Leading Worldwide Patent Estate7
. Generex Announces Patent Award for its Core Vaccine Technologies in Japan8
. CoreLab Partners Opens Office in Tokyo, Japan9
. Global Bioinformatics Industry10
. The Scientist Proudly Announces the Top 10 Innovations of 201211
. Bayer CropScience Announces LibertyLink LinkUp Offer Increased for 2013 Season